AllianceBernstein’s Enanta Pharmaceuticals ENTA Stock Holding History

AllianceBernstein’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$532K	Hold	33,740	–	–	﹤0.01%	2607
2025 Q4	$532K	Hold	33,740	–	–	﹤0.01%	2633
2025 Q3	$404K	Hold	33,740	–	–	﹤0.01%	2798
2025 Q2	$255K	Buy	33,740 +3,800	+13%	+$22.9K	﹤0.01%	2991
2025 Q1	$165K	Hold	29,940	–	–	﹤0.01%	2970
2024 Q4	$172K	Hold	29,940	–	–	﹤0.01%	3050
2024 Q3	$310K	Hold	29,940	–	–	﹤0.01%	2902
2024 Q2	$388K	Buy	29,940 +2,010	+7%	+$27.1K	﹤0.01%	2806
2024 Q1	$488K	Hold	27,930	–	–	﹤0.01%	2593
2023 Q4	$263K	Sell	27,930 -2,740	-9%	-$25.5K	﹤0.01%	2899
2023 Q3	$343K	Buy	30,670 +8,460	+38%	+$136K	﹤0.01%	2751
2023 Q2	$475K	Buy	22,210 +2,670	+14%	+$78.7K	﹤0.01%	2664
2023 Q1	$790K	Sell	19,540 -2,875	-13%	-$137K	﹤0.01%	2338
2022 Q4	$1.04M	Sell	22,415 -28,614	-56%	-$1.3M	﹤0.01%	2248
2022 Q3	$2.65M	Sell	51,029 -75,175	-60%	-$4.39M	﹤0.01%	1706
2022 Q2	$5.97M	Buy	126,204 +15,475	+14%	+$840K	﹤0.01%	1380
2022 Q1	$7.88M	Buy	110,729 +50,875	+85%	+$3.31M	﹤0.01%	1370
2021 Q4	$4.48M	Buy	59,854 +36,604	+157%	+$2.87M	﹤0.01%	1683
2021 Q3	$1.32M	Sell	23,250 -2,400	-9%	-$119K	﹤0.01%	2390
2021 Q2	$1.13M	Hold	25,650	–	–	﹤0.01%	2485
2021 Q1	$1.26M	Buy	25,650 +80	+0.3%	+$3.99K	﹤0.01%	2311
2020 Q4	$1.08M	Hold	25,570	–	–	﹤0.01%	2264
2020 Q3	$1.17M	Sell	25,570 -3,570	-12%	-$173K	﹤0.01%	2112
2020 Q2	$1.46M	Hold	29,140	–	–	﹤0.01%	2012
2020 Q1	$1.5M	Hold	29,140	–	–	﹤0.01%	1841
2019 Q4	$1.8M	Sell	29,140 -22,160	-43%	-$1.37M	﹤0.01%	2018
2019 Q3	$3.08M	Sell	51,300 -3,000	-6%	-$223K	﹤0.01%	1673
2019 Q2	$4.58M	Buy	54,300 +8,700	+19%	+$783K	﹤0.01%	1471
2019 Q1	$4.36M	Hold	45,600	–	–	﹤0.01%	1450
2018 Q4	$3.23M	Buy	45,600 +1,770	+4%	+$136K	﹤0.01%	1542
2018 Q3	$3.75M	Buy	43,830 +2,500	+6%	+$250K	﹤0.01%	1483
2018 Q2	$4.79M	Buy	41,330 +6,100	+17%	+$609K	﹤0.01%	1277
2018 Q1	$2.85M	Sell	35,230 -47,030	-57%	-$3.62M	﹤0.01%	1580
2017 Q4	$4.83M	Sell	82,260 -9,860	-11%	-$494K	﹤0.01%	1241
2017 Q3	$4.31M	Buy	92,120 +22,300	+32%	+$896K	﹤0.01%	1310
2017 Q2	$2.51M	Sell	69,820 -6,090	-8%	-$195K	﹤0.01%	1678
2017 Q1	$2.34M	Sell	75,910 -56,150	-43%	-$1.75M	﹤0.01%	1695
2016 Q4	$4.42M	Sell	132,060 -4,570	-3%	-$131K	﹤0.01%	1266
2016 Q3	$3.64M	Buy	136,630 +71,070	+108%	+$1.65M	﹤0.01%	1319
2016 Q2	$1.45M	Buy	65,560 +36,810	+128%	+$964K	﹤0.01%	1976
2016 Q1	$844K	Buy	28,750 +4,710	+20%	+$131K	﹤0.01%	2196
2015 Q4	$794K	Buy	24,040 +500	+2%	+$16.3K	﹤0.01%	2244
2015 Q3	$851K	Sell	23,540 -60	-0.3%	-$2.58K	﹤0.01%	2248
2015 Q2	$1.06M	Buy	23,600 +9,300	+65%	+$362K	﹤0.01%	2240
2015 Q1	$438K	Buy	14,300 +4,000	+39%	+$156K	﹤0.01%	2545
2014 Q4	$524K	Hold	10,300	–	–	﹤0.01%	2501
2014 Q3	$408K	Buy	10,300 +2,500	+32%	+$99.6K	﹤0.01%	2565
2014 Q2	$336K	Buy	7,800 +7,724	+10,163%	+$295K	﹤0.01%	2637
2014 Q1	$3K	Hold	76	–	–	﹤0.01%	3366
2013 Q4	$2K	Sell	76 -500	-87%	-$12.1K	﹤0.01%	3226
2013 Q3	$13K	Sell	576 -776	-57%	-$14.8K	﹤0.01%	3134
2013 Q2	$24K	Buy	+1,352	New	+$26.4K	﹤0.01%	3058

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AllianceBernstein's ENTA Position: Q1 2026 in Review

AllianceBernstein held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 33,740 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #2607.

AllianceBernstein first reported a position in ENTA in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.88M in Q1 2022. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

AllianceBernstein held 33,740 shares of Enanta Pharmaceuticals worth $532K as of Q1 2026.
AllianceBernstein left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
Enanta Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2607 holding.
AllianceBernstein first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
AllianceBernstein's Enanta Pharmaceuticals position peaked at $7.88M in Q1 2022.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.